Silicon Valley Capital Partners’s Takeda Pharmaceutical TAK Stock Holding History

Silicon Valley Capital Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$625	Hold	39	–	–	﹤0.01%	365
2026 Q1	$722	Buy	+39	New	+$684	﹤0.01%	352

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Silicon Valley Capital Partners's TAK Position: Q2 2026 in Review

Silicon Valley Capital Partners held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 39 shares worth $625. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Silicon Valley Capital Partners first reported a position in TAK in Q1 2026 and has held it in 2 quarters since. The position peaked at $722 in Q1 2026. 379 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Silicon Valley Capital Partners held 39 shares of Takeda Pharmaceutical worth $625 as of Q2 2026.
Silicon Valley Capital Partners left its Takeda Pharmaceutical share count unchanged in Q2 2026.
Takeda Pharmaceutical made up ﹤0.01% of Silicon Valley Capital Partners's portfolio in Q2 2026, its #365 holding.
Silicon Valley Capital Partners first reported a position in Takeda Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
Silicon Valley Capital Partners's Takeda Pharmaceutical position peaked at $722 in Q1 2026.
379 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Silicon Valley Capital Partners's 13F filing for Q2 2026, filed 21 Sep 2026.